Aug 08,2023

Early findings of AI study at Frimley Health NHS Foundation Trust show 99.7% accuracy in triaging chest X-rays as normal

Frimley Health NHS Foundation Trust and Qure.ai have announced the early results of a pilot study using an innovative radiology AI solution to read and differentiate between normal and abnormal chest X-rays (CXRs). qXR, a CE class IIb MDR cleared solution developed by Qure, was deployed with the hypothesis to categorise normal x-rays – approximately 40% of the caseload from GP and outpatient requests – and augment overall reporting efficiency. Early results show 99.7% accuracy in triaging CXRs as normal, with the potential to reduce consultant radiologist’s workload by up to 58% by transferring cases to radiographer reporting workload. Additionally, the qXR AI identified all cancer cases, including inconspicuous cancer risk nodules that may traditionally remain unnoticed. This heralds the potential of using AI for early detection and treatment of lung cancer.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 02,2023

Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial

Massive Bio and Asklepieia will utilize their innovative technologies to provide oncologists and patients unparalleled access to crucial clinical trials, personalized cancer treatments, and reports on adequate therapies. Plans are underway for future collaborations with BeStrong and Open Health Alliance. “Our collaboration with Asklepieia combines precision medicine with AI-driven clinical trial matching, speeding up the introduction of clinical trials in Greece,” Cagatay M. Culcuoglu, COO, CTO, and Co-Founder of Massive Bio said.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Aug 01,2023

Massive Bio Joins FindHealthClinics – Expanding Online Reach in the Healthcare Sector

Massive Bio has recently been added to FindHealthClinics, a trusted online directory catering to the healthcare and wellness industries. This significant development marks a new chapter for Massive Bio as it joins a community of esteemed institutions, clinics, practitioners, and businesses in the field of healthcare. FindHealthClinics serves as a robust platform that connects individuals actively seeking medical, health, and wellness services with reputable professionals and institutions like Massive Bio. With this inclusion, the company gains access to a vast audience of potential clients looking for advanced medical treatments, holistic therapies, wellness services, and more. By utilizing the platform, Massive Bio can expand its online presence, allowing it to reach a broader audience in search of healthcare solutions.

COLLABORATION PARTNERSHIP

#institution

#platform

View Analyst & Ambassador Comments
Go to original news
Aug 01,2023

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

Veracyte announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study analyzed data from 8,297 patients in the SEER registry who received a primary prostate cancer diagnosis from 2010 to 2018 and underwent Decipher Prostate testing. Researchers evaluated the association between the patients’ Decipher scores (range 0-1) and risk groups (low, intermediate and high), and the use of active surveillance and watchful waiting (AS/WW) as well as adverse pathology at the time of radical prostatectomy (RP). The results demonstrated that AS/WW was highest among subjects with low-risk Decipher biopsy results (41%), compared to those who had intermediate-risk (27%) or high-risk (11%) scores. Among subjects with clinically low-risk prostate cancer, 65% of those with low-risk Decipher results were managed with AS/WW. "This study is further evidence that the Decipher Prostate test provides valuable clinical information to physicians and their patients with prostate cancer. In contemporary practice, physicians treat patients with higher-risk Decipher scores more aggressively, and patients with lower-risk Decipher scores more conservatively,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 08,2023

Canopy Joins CancerX to Advance Oncology Care

Canopy, the first Intelligent Care Platform for oncology, today announced its commitment to CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH). CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of The White House’s reignited national Cancer Moonshot initiative. As a CancerX member, Canopy will collaborate with other leaders in the oncology and digital health space to set priorities and practices that will help harness the full power of innovation to achieve the goals of the Cancer Moonshot.

View Analyst & Ambassador Comments
Go to original news
Jun 29,2023

Hawaii Cancer Care Partners with Canopy

Hawaii Cancer Care has partnered with Canopy to further transform patient outcomes and experiences through continuous care delivery and the implementation of a value-based program, Principal Care Management (PCM). Using the Canopy Program Management solution, Hawaii Cancer Care was able to deploy PCM rapidly and enrolled 200 patients in just a few months, resulting in a 5x ROI. Now, Hawaii Cancer Care plans to deploy Canopy’s platform to further enhance continuous care delivery, including Canopy’s electronic patient-reported outcomes (ePRO) solution with integrated triage pathways and intelligent task management tools for remote symptom management and patient engagement.

COLLABORATION PARTNERSHIP

#institution

#rpm

View Analyst & Ambassador Comments
Go to original news
May 31,2023

Canopy Publishes Research at 2023 American Society of Clinical Oncology Meeting

Canopy today announced results from a 21-month, real-world study demonstrating that electronic patient-reported outcomes (ePROs) can help identify common side effects in lung cancer patients receiving immunotherapy, both as monotherapy and in combination with chemotherapy. Regardless of treatment type, patients receiving less than 6 months of therapy were more likely to report severe symptoms than those on treatment for 6 months or longer. The identification of key symptomatic differences in patients with shorter duration of therapy could suggest that aggressive early management can extend time on therapy, leading to improved outcomes. 

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 19,2022

Canopy Findings Published in Journal of Clinical Oncology

Canopy today announced results from a seventeen-month, real-world study of their ePRO-based patient monitoring platform. The single-site study of 923 patients at Highlands Oncology Group demonstrates the Canopy platform can be effectively implemented at a large scale with a high level of long-term patient enrollment, engagement, and retention. The study also found that the vast majority of patient issues were effectively resolved by nurse specialists and physician intervention was infrequently required. 

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 28,2019

Bristol-Myers Squibb and ConcertAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations

Bristol-Myers Squibb and ConcertAI today announced a multi-year strategic agreement that will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials, enable robust protocol design and generate insights for precision treatment and improved patient outcomes. Bristol-Myers Squibb will use ConcertAI’s Real-World Data and novel AI insights platform, eurekaHealth™, to accelerate insights through novel health economic outcomes and clinical development synthetic control arm studies. With this agreement, the companies will advance the use of RWE for regulatory purposes, validate clinical application of AI solutions and execute clinical studies to advance patient care.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 04,2022

CPT Code granted by American Medical Association to LungLife AI

LungLife AI, a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT Proprietary Laboratory Analyses (PLA) code for its LungLB test by the American Medical Association (AMA). The new code has been approved and published by the AMA Editorial Panel and is scheduled to become effective on 1 April 2022. The successful granting of a CPT code marks the first step on the path for commercial reimbursement.

PRODUCT

#reimbursement

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY